S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024

Kura Oncology (KURA) Stock Price, News & Analysis

$21.17
+0.75 (+3.67%)
(As of 03/27/2024 ET)
Today's Range
$20.27
$21.23
50-Day Range
$13.42
$23.53
52-Week Range
$7.41
$24.17
Volume
654,368 shs
Average Volume
1.12 million shs
Market Capitalization
$1.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.28

Kura Oncology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
33.6% Upside
$28.28 Price Target
Short Interest
Healthy
16.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$1.95 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.35) to ($2.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.16 out of 5 stars

Medical Sector

194th out of 939 stocks

Pharmaceutical Preparations Industry

78th out of 431 stocks

KURA stock logo

About Kura Oncology Stock (NASDAQ:KURA)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

KURA Stock Price History

KURA Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
KURA Jul 2024 22.500 call
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
TD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)
Q4 2023 Kura Oncology Inc Earnings Call
KURA Mar 2024 25.000 call
KURA Mar 2024 22.500 put
KURA Mar 2024 30.000 call
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.28
High Stock Price Target
$37.00
Low Stock Price Target
$10.50
Potential Upside/Downside
+33.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-152,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.35 per share

Miscellaneous

Free Float
71,873,000
Market Cap
$1.61 billion
Optionable
Optionable
Beta
0.86
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 55)
    Ph.D., Chairman, CEO & President
    Comp: $1.06M
  • Ms. Kathleen Ford (Age 77)
    Chief Operating Officer
    Comp: $754.24k
  • Dr. Stephen Dale M.D. (Age 52)
    Chief Medical Officer
    Comp: $684.41k
  • Mr. Thomas Doyle (Age 53)
    Senior Vice President of Finance & Accounting
  • Mr. Pete De Spain
    Executive Vice President of Investor Relations & Corporate Communications
  • Ms. Teresa Brophy Bair Esq. (Age 53)
    J.D., Chief Legal Officer & Corporate Secretary
  • Dr. Roger Bakale Ph.D.
    Senior Vice President of Manufacturing & Supply Chain
  • Ms. Maureen Clancy M.B.A.
    VP and Global Head of Program Leadership & Project Management
  • Dr. Mollie Leoni M.D.
    Executive Vice President of Clinical Development
  • Mr. Brian T. Powl M.B.A. (Age 50)
    M.S., Chief Commercial Officer

KURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KURA shares.
View KURA analyst ratings
or view top-rated stocks.

What is Kura Oncology's stock price target for 2024?

8 equities research analysts have issued 1 year target prices for Kura Oncology's stock. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's stock price to reach $28.28 in the next twelve months. This suggests a possible upside of 33.6% from the stock's current price.
View analysts price targets for KURA
or view top-rated stocks among Wall Street analysts.

How have KURA shares performed in 2024?

Kura Oncology's stock was trading at $14.38 at the beginning of the year. Since then, KURA stock has increased by 47.2% and is now trading at $21.17.
View the best growth stocks for 2024 here
.

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our KURA earnings forecast
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same quarter in the prior year, the company posted ($0.49) EPS.

What ETF holds Kura Oncology's stock?

Simplify Propel Opportunities ETF holds 80,000 shares of KURA stock, representing 0.79% of its portfolio.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.68%), Vanguard Group Inc. (5.30%), Vanguard Group Inc. (5.30%), Armistice Capital LLC (2.99%), Dimensional Fund Advisors LP (2.70%) and Franklin Resources Inc. (1.82%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Teresa Brophy Bair, Thomas James Doyle, Thomas Malley and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KURA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners